Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.
Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.
Large B-Cell Lymphoma
Maintenance Bladder Cancer
Stage 2 Non-small Cell Lung Cancer Post Chemoradiation
Relapsed/Refractory Large B Cell Lymphoma
B-Cell Acute Lymphoblastic Leukemia